{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044756","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.482189+00:00","generated_at":"2026-05-30T01:44:12.368196+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Xtant Medical Q3 revenue $27.9M (+12% YoY); reaffirms FY2024 guidance $116-120M","bullets":["Revenue $27.9M (+12% YoY); YTD revenue $85.8M (+36% YoY).","Net loss $5.0M vs net income $9.2M in Q3 2023, which included $11M bargain purchase gain.","Adjusted EBITDA loss $196K vs $440K gain; gross margin 58.4% down from 61.3%.","Reaffirmed FY2024 revenue guidance $116-120M, representing 27-31% annual growth.","Launched OsteoVive+ and Cortera system; signed license agreement for minimum $5.25M in fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044756","json":"https://secwatch.observer/filing/0001493152-24-044756.json","markdown":"https://secwatch.observer/filing/0001493152-24-044756.md","text":"https://secwatch.observer/filing/0001493152-24-044756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224044756/0001493152-24-044756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315224044756/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:44:12.368196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}